Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Board to convene technical advisory committee to evaluate newborn screening for MLD
Summary
After discussion that metachromatic leukodystrophy (MLD) was added to the national RUSP in December 2025 and that gene therapy exists but is costly, the Board declined immediate rulemaking and directed staff to convene a TAC to evaluate MLD for Washington’s newborn screening panel.
The Washington State Board of Health on March 12 declined to add metachromatic leukodystrophy (MLD) directly to the state newborn screening (NBS) panel and instead directed staff to convene a Technical Advisory Committee (TAC) to evaluate the condition under the Board’s established criteria.
Board staff noted that MLD was added to the Recommended Uniform Screening Panel (RUSP) in December 2025 and that an…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat